[HTML][HTML] Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials
CTR Vegivinti, KW Evanson, H Lyons, I Akosman… - BMC Infectious …, 2022 - Springer
Abstract Background Coronavirus disease 2019 (COVID-19) continues to pose a significant
threat to public health worldwide. The purpose of this study was to review current evidence …
threat to public health worldwide. The purpose of this study was to review current evidence …
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up
Cardiovascular Research, 2022 - academic.oup.com
Aims Since its emergence in early 2020, the novel severe acute respiratory syndrome
coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels …
coronavirus 2 causing coronavirus disease 2019 (COVID-19) has reached pandemic levels …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2021 - thelancet.com
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
[HTML][HTML] ESCMID COVID-19 living guidelines: drug treatment and clinical management
M Bartoletti, O Azap, A Barac, L Bussini… - Clinical microbiology …, 2022 - Elsevier
Abstract Scope In January 2021, the ESCMID Executive Committee decided to launch a new
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …
initiative to develop ESCMID guidelines on several COVID-19-related issues, including …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group, PW Horby… - Medrxiv, 2021 - medrxiv.org
Background REGEN-COV is a combination of 2 monoclonal antibodies (casirivimab and
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …
imdevimab) that bind to two different sites on the receptor binding domain of the SARS-CoV …
[HTML][HTML] Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2022 - ncbi.nlm.nih.gov
Background Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients …
[HTML][HTML] Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline
JD Chalmers, ML Crichton… - European respiratory …, 2021 - Eur Respiratory Soc
Introduction Hospitalised patients with coronavirus disease 2019 (COVID-19) as a result of
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have a high …
[HTML][HTML] Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - The Lancet Respiratory Medicine, 2021 - Elsevier
Background Colchicine has been proposed as a treatment for COVID-19 based on its anti-
inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients …
inflammatory actions. We aimed to evaluate the efficacy and safety of colchicine in patients …